Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

No Love From US: Senate Bill Deals Blow To Aspiring China Biotechs

Executive Summary

In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.

You may also be interested in...



Asia Life Sciences IPO Landscape: China, Hong Kong March Ahead But Watch India

Four key Asian markets witnessed nearly 200 life science company listings over the past 10 years, with China dominating the scene and expected to stay ahead, along with Hong Kong, for the foreseeable future. But India could prove a new contender over time as firms move up the value chain, a new report shows.

BeyondSpring's Next Move Uncertain After Plinabulin CRL

Chinese firm BeyondSpring dealt a setback after the US FDA refuses to approve plinabulin for chemotherapy-induced neutropenia.

China mRNA Player Abogen Gets $300m More As Country Eyes Omicron Threat

From inactivated virus-based to mRNA platforms, the race is on in China to develop vaccines to fight the latest omicron variant, with substantial new funding pouring into one young mRNA company.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel